Ichnos Sciences signs licensing pact with Astria Therapeutics for OX40 antagonist monoclonal… EP News Bureau Oct 12, 2023 Astria Therapeutics is granted global rights to develop and commercialise OX40 portfolio, comprised of Telazorlimab and its…
Eli Lilly enters into $960 million deal with Rigel Pharma to develop autoimmune therapy Reuters Feb 19, 2021 Under the deal, Lilly will foot the costs of global commercialisation for the therapy, R552, and Rigel will have the right to…
